Selected Publications


  1. Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark (Rider) JR, Adami H-O, Andersson S-O, Andrén O, Eisenstein AS, Holmberg L, Huang W, Kantoff PW, Kim R, Perner S, Stampfer MJ, Johansson J-E, Rubin MA. Nine-gene molecular signature in tumors does not predict prostate cancer death. Cancer Epidemiol Biomarkers Prev 2008;17(1):249-51.
  2. Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark (Rider) JR, Adami H-O, Andersson S-O, Andren O, Holmberg L, Huang W, Kantoff PW, Kim R, Perner S, Stampfer MJ, Johansson J-E, Rubin MA. Testing of a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev 2008;17(7):1682-8.
  3. Fall K, Stark (Rider) JR, Mucci LA, Chan J, Stampfer MJ, Kurth T, Febbo PG, Kantoff P, Ma J. No association between a polymorphic variant of the IRS-1 gene and prostate cancer risk. Prostate 2008;68(13):1416-20.
  4. Stark (Rider) JR, Li H, Kraft P, Kurth T, Giovannucci EL, Stampfer, MJ, Ma J, Mucci LA. Circulating pre-diagnostic interleukin-6 and c-reactive protein, interleukin-6 genotype, and prostate cancer incidence and mortality. Int J Cancer 2009;124(11):2683-9.
  5. Stark (Rider) JR, Wiklund F, Grönberg H, Schumacher F, Sinnott JA, Stampfer MJ, Mucci LA, Kraft P. Toll-like receptor signaling pathway variants and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2009;18(6):1859-63.
  6. Stark (Rider) JR, Perner S, Stampfer MJ, Sinnott JA, Finn S, Eisenstein A, Ma J, Kurth T, Loda M, Giovannucci EL, Rubin MA, Mucci LA. Gleason score and lethal prostate cancer: Does 3+4 = 4+3?. J Clin Oncol 2009;27(21):3459-64. [Featured as news item in Nat Rev Urol]
  7. Mucci LA, Stark (Rider) JR, Figg WD, Schumacher F, Li H, Abe M, Hennessey K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW. Polymorphism in endostatin, an angiogenesis inhibitor, and prostate cancer risk and survival: a prospective study. Int J Cancer 2009;125(5):1143-1146.
  8. Stark (Rider) JR, Judson G, Alderete JF, Mundodi V, Kucknoor AS, Giovannucci EL, Platz EA, Sutcliffe S, Fall K, Kurth T, Ma J, Stampfer MJ, Mucci LA. Trichomonas vaginalis infection and prostate cancer incidence and mortality: a prospective study in the Physicians’ Health Study. J Natl Cancer Inst 2009;101(20):1406-11.[Accompanying editorial]
  9. Mucci LA, Stark (Rider) JR, Pollak MN, Li H, Kurth T, Stampfer MJ, Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-1, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2010;19(2):484-91.
  10. Fiorentino M, Judson G, Penney K, Flavin R, Stark (Rider) JR, Fiore C, Fall K, Martin NE, Ma J, Sinnott JA, Giovannucci E, Stampfer MJ, Sesso H, Kantoff PW, Finn S, Loda M, Mucci LA. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res 2010;70(8):3136-9.
  11. Meyer MS, Penney KL, Stark (Rider) JR, Schumacher F, Sesso H, Loda M, Fiorentino M, Finn S, Flavin R, Kurth T, Price A, Giovannucci EL, Fall K, Stampfer MJ, Ma J, Mucci LA. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis 2010;31(9):1597-603.
  12. Kirrander P, Kolaric A, Helenius G, Windahl T, Andrén O, Stark (Rider) JR, Lillsunde-Larsson G, Elgh F, Karlsson MG. Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large Swedish cohort of men with penile carcinoma. BJU Int  2011;108(3)355-9.
  13. Andersson S-O, Andrén O, Lyth J, Stark (Rider) JR, Henriksson M, Adami H-O, Carlsson P, Johansson JE. Managing localized prostate cancer by radical prostatectomy or watchful waiting: cost analysis of a randomized trial (SPCG-4). Scand J Urol Nephrol 2011;45(3):177-183.
  14. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark (Rider) JR, Busch C, Nordling S, Häggman M, Andersson S-O, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami H-O, Johansson J-E. Radical  prostatectomy versus watchful  waiting in early prostate cancer – a 15-year follow-up. New England J Med 2011;364(18):1708-17.
  15. Penney K, Sinnott JA, Fall K, Pawitan Y, Hoshida Y, Kraft P, Stark (Rider) JR, Fiorentino M, Perner S, Finn SP, Calza S, Flavin R, Freedman M, Setlur S, Sesso H, Andersson S-O, Martin N, Kantoff PW, Johansson J-E, Adami H-O, Rubin MA, Loda M, Golub TR, Andrén O, Stampfer MJ, Mucci LA. An mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. J Clin Oncol 2011;29(17):2391-6.
  16. Wilson KM, Kasperzyk JL, Rider JR, Kenfield S, van Dam RM, Stampfer MJ, Giovannucci E, Mucci LA. Coffee Consumption and Prostate Cancer Risk and Progression in the Health Professionals Follow-up Study. J Natl Cancer Inst 2011;103(11):876-84.
  17. Davidsson S, Fiorentino M, Andren O, Fang F, Mucci LA, Varenhorst E, Fall K, Rider JR. Inflammation, focal atrophic lesions and prostatic intraepithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20(10):2280-7.
  18. Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollack M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci EL, Stampfer MJ, Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2011;20(12):2618-27.
  19. Shui IM, Stark (Rider) JR, Penney KL, Schumacher FR, Epstein MM, Pitt MJ, Stampfer MJ, Tamimi RM, Lindstrom, S, Sesso HD, Fall K, Ma J, Kraft P, Giovannucci E, Mucci LA. Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality. Prostate 2012;72(2):209-16.
  20. Sigurdardottir LG, Valdimarsdottir U, Fall K, Rider JR, Lockley SW, Eva SS, Mucci LA. Circadian disruption, sleep loss and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2012;21(7):1002-11.
  21. Pettersson A, Graff RE, Bauer SR, Pitt M, Lis RT, Stack EC, Martin NE, Kunz L, Penney KL, Ligon AH, Suppan C, Flavin R, Sesso HD, Rider JR, Sweeney C, Stampfer M, Fiorentino M, Kantoff PW, Sanda M, Giovannucci E, Ding EL, Loda M, Mucci LA. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidmiol Biomarkers Prev 2012;21:1497-1509.
  22. Epstein MM, Edgren G, Rider JR, Mucci LA, Adami H-O. Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 2012;104(17):1335-42.
  23. Epstein MM, Andrén O, Kasperzyk JL, Shui IM, Penney KL, Fall K, Rider JR, Stampfer MJ, Andersson S-O, Giovannucci E, Mucci LA. Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control 2012;104(17):1335-42.
  24. Rider JR, Sandin F, Andrén O, Wiklund P, Hugosson J, Stattin P. Long-term outcomes among non-curatively treated men according to prostate cancer risk category in a nation-wide, population-based study. Eur Urol 2013;63(1):88-96.
  25. Chen YC, Huang YL, Platz EA, Alderete JF, Zheng L, Rider JR, Kraft P, Giovannucci E, Sutcliffe S. Prospective study of effect modification by Toll-like receptor 4 variation on the association between Trichomonas vaginalis serostatus and prostate cancer. Cancer Causes Control 2013;24(1):175-80.
  26. Rider JR, Popiolek M, Andrén O, Andersson S-O, Holmberg L, Adami H-O, Johansson J-E. Natural history of early, localized prostate cancer: a final report from three decades of follow up. Eur Urol 2012;63(3):428-35.
  27. Davidsson S, Ohlson A-L, Andersson S-O, Fall K, Meisner A, Fiorentino M, Andrén O, Rider JR. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3+ regulatory T cells with respect to lethal prostate cancer. Modern Pathology 2012 [In Press].
  • Bill-Axelson A, Garmo H, Holmberg L, Johansson J-E, Adami H-O, Steineck G, Johansson E, Rider JR. Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the SPCG-4 clinical trial. Eur Urol 2013 [In Press].